701 related articles for article (PubMed ID: 33332697)
1. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
[TBL] [Abstract][Full Text] [Related]
2. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
6. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
Patruno C; Fabbrocini G; Longo G; Argenziano G; Ferrucci SM; Stingeni L; Peris K; Ortoncelli M; Offidani A; Amoruso GF; Talamonti M; Girolomoni G; Grieco T; Iannone M; Nettis E; Foti C; Rongioletti F; Corazza M; Veneri MD; Napolitano M;
Am J Clin Dermatol; 2021 Jul; 22(4):581-586. PubMed ID: 33725337
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
[TBL] [Abstract][Full Text] [Related]
12. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C
Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611
[TBL] [Abstract][Full Text] [Related]
14. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C
Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393
[TBL] [Abstract][Full Text] [Related]
16. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
Napolitano M; Fabbrocini G; Potestio L; Fontanella G; Picone V; Bennardo L; Scalvenzi M; Patruno C
Dermatol Ther; 2022 Aug; 35(8):e15588. PubMed ID: 35569129
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Sun X; Chen Z; Akinlade B; Boklage S; Guillemin I; Kosloski MP; Kamal MA; O'Malley JT; Patel N; Graham NMH; Bansal A
Br J Dermatol; 2021 May; 184(5):857-870. PubMed ID: 32969489
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.
Hosseini-Ashrafi M; Clayton TH; Herring M; Herety N; Arkwright PD
Clin Exp Dermatol; 2024 May; 49(6):578-583. PubMed ID: 38189448
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
Chia SY; Wee LWY; Koh MJA
Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
[TBL] [Abstract][Full Text] [Related]
20. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.
Jang DH; Heo SJ; Kook HD; Lee DH; Jung HJ; Park MY; Ahn J
Sci Rep; 2021 Dec; 11(1):23539. PubMed ID: 34876623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
